Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy

Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy

BackgroundImmune checkpoint inhibitors (ICIs) brought about a major paradigm shift in non-small cell lung cancer (NSCLC) treatment. However, the use of ICIs is related to an unforeseeable pattern of immune-related adverse events (irAEs). Hence, more precise biomarkers are needed to predict the incid...

Full description

Bibliographic Details
Main Authors: Haowei Wang, Fei Zhou, Chao Zhao, Lei Cheng, Caicun Zhou, Meng Qiao, Xuefei Li, Xiaoxia Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-02-01
Series:Frontiers in Immunology
Subjects:
immunotherapy
toxicity
interleukin−10
immune−related adverse events
NSCLC
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.840313/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.840313/full

Similar Items